Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | DRD4 | P21917 | 4/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.45 |
| ▸ | UTS2R | Q9UKP6 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5771860 | 0.92 | CCR3 (0.77) | CCR3KMT2AMEN1EPHX2DRD4 | |
| SCHEMBL5778423 | 0.92 | CCR3 (0.77) | CCR3KMT2AMEN1EPHX2DRD4 | |
| SCHEMBL5774254 | 0.91 | CCR3 (0.73) | CCR3KMT2AMEN1EPHX2DRD4 | |
| SCHEMBL5778335 | 0.90 | CCR3 (0.70) | CCR3KMT2AMEN1EPHX2DRD4 | |
| SCHEMBL5774562 | 0.90 | CCR3 (0.70) | CCR3KMT2AMEN1EPHX2DRD4 | |
| SCHEMBL6558579 | 0.89 | CCR3 (0.69) | CCR3KMT2AMEN1EPHX2DRD4 | |
| SCHEMBL5773969 | 0.89 | CCR3 (0.69) | CCR3KMT2AMEN1EPHX2DRD4 | |
| SCHEMBL5832976 | 0.89 | CCR3 (0.55) | CCR3KMT2AMEN1EPHX2DRD4 | |
| SCHEMBL4023368 | 0.89 | CCR3 (0.55) | CCR3KMT2AMEN1EPHX2DRD4 | |
| SCHEMBL5778646 | 0.87 | CCR3 (0.83) | CCR3KMT2AMEN1EPHX2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1487455-A1 | MORPHOLINE DERIVATIVES SUBSTITUTED AT THE 2-POSITION BY AN ARYLALKYLUREA GROUP FOR USE AS CCR-3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY CONDITIONS | GLAXO GROUP LIMITED (GB) | 2004-12-22 | — | — | EP | claimed |
| WO-2003082292-A1 | MORPHOLINE DERIVATIVES SUBSTITUTED AT THE 2-POSITION BY AN ARYLALKYLUREA GROUP FOR USE AS CCR-3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY CONDITIONS | GLAXO GROUP LIMITED (GB) | 2003-10-09 | — | — | WO | claimed |
| EP-1324991-B1 | COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
| EP-1487455-A1 | MORPHOLINE DERIVATIVES SUBSTITUTED AT THE 2-POSITION BY AN ARYLALKYLUREA GROUP FOR USE AS CCR-3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY CONDITIONS | GLAXO GROUP LIMITED (GB) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003082292-A1 | MORPHOLINE DERIVATIVES SUBSTITUTED AT THE 2-POSITION BY AN ARYLALKYLUREA GROUP FOR USE AS CCR-3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY CONDITIONS | GLAXO GROUP LIMITED (GB) | 2003-10-09 | — | — | WO | disclosed |